Collaborative Research and Licensing Opportunity: A bivalent conjugate vaccine for Malaria and Typhoid prophylaxis

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID) have developed a novel bivalent vaccine candidate that may effectively prevent malaria and typhoid. This approach significantly enhances immune response to the Pfs25 Malaria transmission blocking antigen and produces a robust immune response against Salmonella typhi Vi polysaccharide (ViP).

Malaria is the single leading cause of mortality, especially among children in the developing world. Typhoid fever, caused by infection with Salmonella typhi, is known to be endemic with malaria and causes its own significant disease burden. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have developed a novel bivalent vaccine candidate that may effectively prevent malaria and typhoid. This approach significantly enhances immune response to the Pfs25 Malaria transmission blocking antigen and produces a robust immune response against Salmonella typhi Vi polysaccharide (ViP).

Potential Commercial Applications:

Development of this technology into a vaccine may protect vulnerable populations from both Malaria transmission and Typhoid fever.

Competitive Advantages:

This technology has significant advantages over current treatments, since there is currently only one commercial Malaria vaccine licensed for use in Europe only, which was not developed to address Malaria transmission, and the currently licensed Salmonella typhi vaccines show incomplete efficacy and do not provide long-term immunity.A formulation of the present technology has shown the ability to induce an immune response to Pfs25 in excess of 100 times higher and Salmonella typhi antigen 20-40 times higher than what is seen by immunization with either antigen alone.

Development Stage:

In vivo data available (animal)

Intellectual Property:

HHS Ref # E-124-2016/0: Provisional Patent application # 62/327,184 Filed 04/25/16

Collaborative Research Opportunity:

The NIAID, Laboratory of Malaria Immunology and Vaccinology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology.

Contact:

Please contact Dr. Daniel Anacker at 301-761-7671 or daniel.anacker@nih.gov for more information.


Go to the profile of NIAID Technology Transfer and Intellectual Property Office

NIAID Technology Transfer and Intellectual Property Office

NIAID’s technology transfer office, TTIPO, is a one-stop resource for organizations interested in partnering with NIAID to access, develop, and manage the translation of research discoveries into medically beneficial products. TTIPO seeks to expand NIAID’s innovation pipeline with existing and new partners in areas such as newly emerging and re-emerging infectious diseases (e.g., dengue, Zika, Ebola, influenza, methicillin-resistant Staphylococcus aureus and HIV/AIDS), biodefense (e.g., smallpox and anthrax), and immune-mediated diseases (e.g., asthma and allergy).

No comments yet.